Baseline characteristics of patients with metabolic syndrome (based on ≥3 risk factors) and without diabetes at baseline in REDUCE-IT
| . | Icosapent ethyl (N = 1453) . | Placebo (N = 1413) . | Overall (N = 2866) . | P-value . |
|---|---|---|---|---|
| Age (years) | 0.64 | |||
| Median (Q1–Q3) | 62.0 (56.0–68.0) | 63.0 (56.0–69.0) | 62.0 (56.0–69.0) | |
| Age group, n (%) | 0.43 | |||
| <65 years | 857 (59.0) | 813 (57.5) | 1670 (58.3) | |
| ≥65 years | 596 (41.0) | 600 (42.5) | 1196 (41.7) | |
| Sex, n (%) | 0.68 | |||
| Male | 1169 (80.5) | 1128 (79.8) | 2297 (80.1) | |
| Female | 284 (19.5) | 285 (20.2) | 569 (19.9) | |
| Race, n (%) | 0.20 | |||
| White | 1366 (94.0) | 1344 (95.1) | 2710 (94.6) | |
| Black | 11 (0.8) | 15 (1.1) | 26 (0.9) | |
| Asian | 56 (3.9) | 37 (2.6) | 93 (3.2) | |
| CV risk category, n (%) | 0.43 | |||
| Secondary prevention cohort | 1449 (99.7) | 1411 (99.9) | 2860 (99.8) | |
| Primary prevention cohort | 4 (0.3) | 2 (0.1) | 6 (0.2) | |
| Waist circumference, n (%) | ||||
| Men ≥40 inches (102 cm) | 769/1169 (65.8) | 753/1128 (66.8) | 1522/2297 (66.3) | 0.78 |
| Women ≥35 inches (88 cm) | 242/284 (85.2) | 258/285 (90.5) | 500/569 (87.9) | 0.06 |
| Hypertension, n (%) | 0.08 | |||
| Yes | 1174 (80.8) | 1177 (83.3) | 2351 (82.0) | |
| No | 279 (19.2) | 236 (16.7) | 515 (18.0) | |
| Impaired fasting glucose metabolism, n (%) | 0.11 | |||
| Yes | 819 (56.4) | 839 (59.4) | 1658 (57.9) | |
| No | 633 (43.6) | 574 (40.6) | 1207 (42.1) | |
| Triglycerides, mg/dL | 0.57 | |||
| Median (Q1–Q3) | 223.0 (183.0–281.0) | 222.5 (183.5–278.5) | 223.0 (183.5–279.5) | |
| LDL-C, mg/dL | 0.27 | |||
| Median (Q1–Q3) | 76.0 (64.0–89.0) | 77.0 (64.0–90.0) | 77.0 (64.0–90.0) | |
| HDL-C, n (%) | ||||
| Men (<40 mg/dL) | 684/1169 (58.5) | 702/1128 (62.2) | 1386/2297 (60.3) | 0.08 |
| Women (<50 mg/dL) | 226/284 (79.6) | 198/285 (69.5) | 424/569 (74.5) | 0.01 |
| hsCRP (mg/L) | 0.28 | |||
| Median (Q1–Q3) | 2.0 (1.0–4.0) | 1.9 (1.0–3.8) | 1.9 (1.0–3.9) |
| . | Icosapent ethyl (N = 1453) . | Placebo (N = 1413) . | Overall (N = 2866) . | P-value . |
|---|---|---|---|---|
| Age (years) | 0.64 | |||
| Median (Q1–Q3) | 62.0 (56.0–68.0) | 63.0 (56.0–69.0) | 62.0 (56.0–69.0) | |
| Age group, n (%) | 0.43 | |||
| <65 years | 857 (59.0) | 813 (57.5) | 1670 (58.3) | |
| ≥65 years | 596 (41.0) | 600 (42.5) | 1196 (41.7) | |
| Sex, n (%) | 0.68 | |||
| Male | 1169 (80.5) | 1128 (79.8) | 2297 (80.1) | |
| Female | 284 (19.5) | 285 (20.2) | 569 (19.9) | |
| Race, n (%) | 0.20 | |||
| White | 1366 (94.0) | 1344 (95.1) | 2710 (94.6) | |
| Black | 11 (0.8) | 15 (1.1) | 26 (0.9) | |
| Asian | 56 (3.9) | 37 (2.6) | 93 (3.2) | |
| CV risk category, n (%) | 0.43 | |||
| Secondary prevention cohort | 1449 (99.7) | 1411 (99.9) | 2860 (99.8) | |
| Primary prevention cohort | 4 (0.3) | 2 (0.1) | 6 (0.2) | |
| Waist circumference, n (%) | ||||
| Men ≥40 inches (102 cm) | 769/1169 (65.8) | 753/1128 (66.8) | 1522/2297 (66.3) | 0.78 |
| Women ≥35 inches (88 cm) | 242/284 (85.2) | 258/285 (90.5) | 500/569 (87.9) | 0.06 |
| Hypertension, n (%) | 0.08 | |||
| Yes | 1174 (80.8) | 1177 (83.3) | 2351 (82.0) | |
| No | 279 (19.2) | 236 (16.7) | 515 (18.0) | |
| Impaired fasting glucose metabolism, n (%) | 0.11 | |||
| Yes | 819 (56.4) | 839 (59.4) | 1658 (57.9) | |
| No | 633 (43.6) | 574 (40.6) | 1207 (42.1) | |
| Triglycerides, mg/dL | 0.57 | |||
| Median (Q1–Q3) | 223.0 (183.0–281.0) | 222.5 (183.5–278.5) | 223.0 (183.5–279.5) | |
| LDL-C, mg/dL | 0.27 | |||
| Median (Q1–Q3) | 76.0 (64.0–89.0) | 77.0 (64.0–90.0) | 77.0 (64.0–90.0) | |
| HDL-C, n (%) | ||||
| Men (<40 mg/dL) | 684/1169 (58.5) | 702/1128 (62.2) | 1386/2297 (60.3) | 0.08 |
| Women (<50 mg/dL) | 226/284 (79.6) | 198/285 (69.5) | 424/569 (74.5) | 0.01 |
| hsCRP (mg/L) | 0.28 | |||
| Median (Q1–Q3) | 2.0 (1.0–4.0) | 1.9 (1.0–3.8) | 1.9 (1.0–3.9) |
Age (years) is at randomization.
Baseline characteristics of patients with metabolic syndrome (based on ≥3 risk factors) and without diabetes at baseline in REDUCE-IT
| . | Icosapent ethyl (N = 1453) . | Placebo (N = 1413) . | Overall (N = 2866) . | P-value . |
|---|---|---|---|---|
| Age (years) | 0.64 | |||
| Median (Q1–Q3) | 62.0 (56.0–68.0) | 63.0 (56.0–69.0) | 62.0 (56.0–69.0) | |
| Age group, n (%) | 0.43 | |||
| <65 years | 857 (59.0) | 813 (57.5) | 1670 (58.3) | |
| ≥65 years | 596 (41.0) | 600 (42.5) | 1196 (41.7) | |
| Sex, n (%) | 0.68 | |||
| Male | 1169 (80.5) | 1128 (79.8) | 2297 (80.1) | |
| Female | 284 (19.5) | 285 (20.2) | 569 (19.9) | |
| Race, n (%) | 0.20 | |||
| White | 1366 (94.0) | 1344 (95.1) | 2710 (94.6) | |
| Black | 11 (0.8) | 15 (1.1) | 26 (0.9) | |
| Asian | 56 (3.9) | 37 (2.6) | 93 (3.2) | |
| CV risk category, n (%) | 0.43 | |||
| Secondary prevention cohort | 1449 (99.7) | 1411 (99.9) | 2860 (99.8) | |
| Primary prevention cohort | 4 (0.3) | 2 (0.1) | 6 (0.2) | |
| Waist circumference, n (%) | ||||
| Men ≥40 inches (102 cm) | 769/1169 (65.8) | 753/1128 (66.8) | 1522/2297 (66.3) | 0.78 |
| Women ≥35 inches (88 cm) | 242/284 (85.2) | 258/285 (90.5) | 500/569 (87.9) | 0.06 |
| Hypertension, n (%) | 0.08 | |||
| Yes | 1174 (80.8) | 1177 (83.3) | 2351 (82.0) | |
| No | 279 (19.2) | 236 (16.7) | 515 (18.0) | |
| Impaired fasting glucose metabolism, n (%) | 0.11 | |||
| Yes | 819 (56.4) | 839 (59.4) | 1658 (57.9) | |
| No | 633 (43.6) | 574 (40.6) | 1207 (42.1) | |
| Triglycerides, mg/dL | 0.57 | |||
| Median (Q1–Q3) | 223.0 (183.0–281.0) | 222.5 (183.5–278.5) | 223.0 (183.5–279.5) | |
| LDL-C, mg/dL | 0.27 | |||
| Median (Q1–Q3) | 76.0 (64.0–89.0) | 77.0 (64.0–90.0) | 77.0 (64.0–90.0) | |
| HDL-C, n (%) | ||||
| Men (<40 mg/dL) | 684/1169 (58.5) | 702/1128 (62.2) | 1386/2297 (60.3) | 0.08 |
| Women (<50 mg/dL) | 226/284 (79.6) | 198/285 (69.5) | 424/569 (74.5) | 0.01 |
| hsCRP (mg/L) | 0.28 | |||
| Median (Q1–Q3) | 2.0 (1.0–4.0) | 1.9 (1.0–3.8) | 1.9 (1.0–3.9) |
| . | Icosapent ethyl (N = 1453) . | Placebo (N = 1413) . | Overall (N = 2866) . | P-value . |
|---|---|---|---|---|
| Age (years) | 0.64 | |||
| Median (Q1–Q3) | 62.0 (56.0–68.0) | 63.0 (56.0–69.0) | 62.0 (56.0–69.0) | |
| Age group, n (%) | 0.43 | |||
| <65 years | 857 (59.0) | 813 (57.5) | 1670 (58.3) | |
| ≥65 years | 596 (41.0) | 600 (42.5) | 1196 (41.7) | |
| Sex, n (%) | 0.68 | |||
| Male | 1169 (80.5) | 1128 (79.8) | 2297 (80.1) | |
| Female | 284 (19.5) | 285 (20.2) | 569 (19.9) | |
| Race, n (%) | 0.20 | |||
| White | 1366 (94.0) | 1344 (95.1) | 2710 (94.6) | |
| Black | 11 (0.8) | 15 (1.1) | 26 (0.9) | |
| Asian | 56 (3.9) | 37 (2.6) | 93 (3.2) | |
| CV risk category, n (%) | 0.43 | |||
| Secondary prevention cohort | 1449 (99.7) | 1411 (99.9) | 2860 (99.8) | |
| Primary prevention cohort | 4 (0.3) | 2 (0.1) | 6 (0.2) | |
| Waist circumference, n (%) | ||||
| Men ≥40 inches (102 cm) | 769/1169 (65.8) | 753/1128 (66.8) | 1522/2297 (66.3) | 0.78 |
| Women ≥35 inches (88 cm) | 242/284 (85.2) | 258/285 (90.5) | 500/569 (87.9) | 0.06 |
| Hypertension, n (%) | 0.08 | |||
| Yes | 1174 (80.8) | 1177 (83.3) | 2351 (82.0) | |
| No | 279 (19.2) | 236 (16.7) | 515 (18.0) | |
| Impaired fasting glucose metabolism, n (%) | 0.11 | |||
| Yes | 819 (56.4) | 839 (59.4) | 1658 (57.9) | |
| No | 633 (43.6) | 574 (40.6) | 1207 (42.1) | |
| Triglycerides, mg/dL | 0.57 | |||
| Median (Q1–Q3) | 223.0 (183.0–281.0) | 222.5 (183.5–278.5) | 223.0 (183.5–279.5) | |
| LDL-C, mg/dL | 0.27 | |||
| Median (Q1–Q3) | 76.0 (64.0–89.0) | 77.0 (64.0–90.0) | 77.0 (64.0–90.0) | |
| HDL-C, n (%) | ||||
| Men (<40 mg/dL) | 684/1169 (58.5) | 702/1128 (62.2) | 1386/2297 (60.3) | 0.08 |
| Women (<50 mg/dL) | 226/284 (79.6) | 198/285 (69.5) | 424/569 (74.5) | 0.01 |
| hsCRP (mg/L) | 0.28 | |||
| Median (Q1–Q3) | 2.0 (1.0–4.0) | 1.9 (1.0–3.8) | 1.9 (1.0–3.9) |
Age (years) is at randomization.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
